Research programme: PPAR pan-agonists for obesity - Plexxikon

Drug Profile

Research programme: PPAR pan-agonists for obesity - Plexxikon

Alternative Names: Nuclear receptor therapeutic for obesity - Plexxikon

Latest Information Update: 06 Apr 2011

Price : $50

At a glance

  • Originator Plexxikon
  • Class Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 04 Apr 2011 Plexxikon has been acquired by Daiichi Sankyo Company
  • 22 Sep 2010 Preclinical development is ongoing
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top